GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (LTS:0RGO) » Definitions » Short Interest

DMS Imaging (LTS:0RGO) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of DMS Imaging's Short Interest

For the Biotechnology subindustry, DMS Imaging's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMS Imaging's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's Short Interest distribution charts can be found below:

* The bar in red indicates where DMS Imaging's Short Interest falls into.


DMS Imaging (LTS:0RGO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (LTS:0RGO) » Definitions » Short Interest
Comparable Companies
XBRU:CYAD XBRU:BIOS XBRU:OXUR XBRU:ONWD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN
Traded in Other Exchanges
AS0:Germany ALIMG:Belgium
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
Website
https://www.dms-imaging.com
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (LTS:0RGO) Headlines

No Headlines